253 related articles for article (PubMed ID: 36815780)
1. Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname.
Bihariesingh-Sanchit R; Bansie R; Ramdhani N; Mangroo R; Bustamente D; Diaz E; Fung A Foek C; Thakoer I; Vreden S; Choudhry Z; van 't Wout AB; Diavatopoulos DA; Nierich AP
mBio; 2023 Apr; 14(2):e0337922. PubMed ID: 36815780
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.
Kirenga B; Byakika-Kibwika P; Muttamba W; Kayongo A; Loryndah NO; Mugenyi L; Kiwanuka N; Lusiba J; Atukunda A; Mugume R; Ssali F; Ddungu H; Katagira W; Sekibira R; Kityo C; Kyeyune D; Acana S; Aanyu-Tukamuhebwa H; Kabweru W; Nakwagala F; Bagaya BS; Kimuli I; Nantanda R; Buregyeya E; Byarugaba B; Olaro C; Mwebesa H; Joloba ML; Siddharthan T; Bazeyo W
BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34376401
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience.
Ateş İ; Erden A; Güven SC; Gürler EK; Çağlayan A; Güçbey Ö; Apaydın H; Şahiner ES; Küçük H; Varan Ö; Omma A; Küçükşahin O
Transfus Apher Sci; 2021 Dec; 60(6):103238. PubMed ID: 34412949
[TBL] [Abstract][Full Text] [Related]
6. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia.
Bar KJ; Shaw PA; Choi GH; Aqui N; Fesnak A; Yang JB; Soto-Calderon H; Grajales L; Starr J; Andronov M; Mastellone M; Amonu C; Feret G; DeMarshall M; Buchanan M; Caturla M; Gordon J; Wanicur A; Monroy MA; Mampe F; Lindemuth E; Gouma S; Mullin AM; Barilla H; Pronina A; Irwin L; Thomas R; Eichinger RA; Demuth F; Luning Prak ET; Pascual JL; Short WR; Elovitz MA; Baron J; Meyer NJ; Degnan KO; Frank I; Hensley SE; Siegel DL; Tebas P
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34788233
[TBL] [Abstract][Full Text] [Related]
8. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
[TBL] [Abstract][Full Text] [Related]
14. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19.
Briggs N; Gormally MV; Li F; Browning SL; Treggiari MM; Morrison A; Laurent-Rolle M; Deng Y; Hendrickson JE; Tormey CA; Desruisseaux MS
PLoS One; 2021; 16(7):e0254453. PubMed ID: 34320004
[TBL] [Abstract][Full Text] [Related]
15. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.
Ipe TS; Ugwumba B; Spencer HJ; Le T; Ridenour T; Armitage J; Ryan S; Pearson S; Kothari A; Patil N; Dare R; Crescencio JCR; Venkata A; Laudadio J; Mohammad K; Jamal N; Thompson J; McNew H; Gibbs M; Hennigan S; Kellar S; Reitzel K; Walser BE; Novak A; Quinn B
Lab Med; 2022 Nov; 53(6):623-628. PubMed ID: 35771890
[TBL] [Abstract][Full Text] [Related]
17. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19.
Körper S; Weiss M; Zickler D; Wiesmann T; Zacharowski K; Corman VM; Grüner B; Ernst L; Spieth P; Lepper PM; Bentz M; Zinn S; Paul G; Kalbhenn J; Dollinger MM; Rosenberger P; Kirschning T; Thiele T; Appl T; Mayer B; Schmidt M; Drosten C; Wulf H; Kruse JM; Jungwirth B; Seifried E; Schrezenmeier H;
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464358
[TBL] [Abstract][Full Text] [Related]
18. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
Trials; 2021 May; 22(1):323. PubMed ID: 33947446
[TBL] [Abstract][Full Text] [Related]
20. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
